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Introduction
Magnetic resonance (MR) image (MRI) guided radia-
tion therapy (MRgRT) confers superior daily soft-tissue
target visualization for many anatomic sites compared
with traditional computed tomography (CT)ebased
radiation therapy and is increasingly used to manage
inter- and intrafraction motion in a variety of cancer di-
agnoses.1,2 There is growing evidence that MRgRT may
be used to improve the dosimetric therapeutic index of
radiation treatment through improved daily setup accu-
racy, the opportunity for daily online plan adaptation, and
real-time cine MRI tumor motion tracking with beam
gating.3 In pediatric patients with cancer, unique
emphasis is placed on maximization of the therapeutic
index to minimize long-term risks of normal tissue
exposure while maximizing durable disease control.
Additionally, the young pediatric population is unable to
actively participate in respiratory breath-hold treatment
techniques for motion management, presenting an addi-
tional challenge and concern for treatment. Herein, we
report the ﬁrst use of MRgRT to treat a pediatric patient in
the case of a 3-year-old girl with rhabdomyosarcoma. In
addition, we describe key technical considerations of
MRgRT use for maximization of safety, setup accuracy,
and intrafraction motion management for the deﬁnitive
treatment of a primary tumor of the diaphragm in a small
child.
Case
A 3-year-old girl presented with sleep difﬁculty and
5 days of abdominal distention with urinary retention. A
CT of the chest and abdomen identiﬁed a 17  10 cm
mass centered at the diaphragm, with mass effect on the
liver and direct extension into the anterior mediastinum,
with a mediastinal component measuring 7 cm  2.7 cm
with compression of the right ventricle (Fig. 1). Subse-
quent ultrasound guided biopsy revealed a diagnosis of
embryonal rhabdomyosarcoma on histopathologic anal-
ysis, with immunohistochemistry staining positive for
vimentin and desmin. Fluorescence in situ hybridization
revealed no evidence for a FOXO1-containing chromo-
somal rearrangement. Positron emission tomographyeCT
imaging and bilateral bone marrow biopsy indicated no
evidence of additional distant metastatic disease. These
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ﬁndings were consistent with intergroup rhabdomyosar-
coma study group T2bN0M0 stage III disease of favor-
able histologic characteristics and unfavorable site.
The patient initiated a chemotherapy regimen
including cycles of vincristine, ifosfamide, etoposide,
dactinomycin, cyclophosphamide, irinotecan, and doxo-
rubicin with ﬁlgrastim support. Interval CT imaging
indicated a partial response to chemotherapy, and the
patient subsequently underwent gross total surgical
resection of her diaphragmatic and mediastinal disease.
Histopathologic examination revealed a 5.8  5.3-cm
primary diaphragmatic tumor with evidence of treatment
response and negative margins, containing a small resid-
ual focus of viable embryonal rhabdomyosarcoma and no
evidence of residual mediastinal disease. Postoperative
CT indicated no evidence of residual or metastatic dis-
ease. The patient reinitiated chemotherapy and was
referred to radiation oncology to consider adjuvant radi-
ation therapy with concurrent chemotherapy.
Considering the pathology ﬁndings from surgery, a
recommendation was made that the primary tumor site
involving the diaphragm be treated with radiation therapy
to a total dose of 36 Gy in 20 daily fractions of 1.8 Gy
using intensity modulated radiation therapy. MR guidance
was selected for maximal setup accuracy and intrafraction
motion management without the additional imaging
dose inherent to CT-guided treatment paradigms with
kilovoltage-based on-board imaging. Given the young age
of the patient, daily anesthesia was required for all treat-
ment fractions.
Treatment Planning and Delivery
Detailed descriptions of the initial planning process,
simulation, and MRgRT treatment device, including its
imaging characteristics and dedicated treatment planning
system (TPS), have been previously published.4-7 For this
pediatric patient, simulation comprised both CT and MRI,
with use of CT as the primary data set. The gross tumor
volume (GTV) was deﬁned as the preoperative visible
tumor volume with modiﬁcations accounting for return of
organs to their normal anatomic position after surgery.
The clinical target volume (CTV) comprised a 1 cm
volumetric expansion on the GTV, with modiﬁcation for
extension into normal organs (eg, heart). The planning
target volume (PTV) was created using a 0.5 cm volu-
metric expansion on the CTV. Treatment target volumes
are shown in Figure 1.
Motion of the target volume was evaluated with use of
4-dimensional CT at the time of simulation. Imaging
indicated movement of the target with breathing. Given
the patient’s age, there was no ability to employ a breath-
hold technique for treatment; the decision was made to
proceed with real-time cine MR beam gating, which has
been previously described in the literature,8 and no
Fig. 1 (A-C) Diaphragmatic rhabdomyosarcoma tumor burden at time of diagnosis. (D and E) Gross target volume (yellow contour),
clinical target volume (green contour), and planning target volume (red contour). (F) 1-, 2-, and 3-Gy isodose lines from the delivered
treatment plan indicate curvature of low-dose isodose lines away from the body under the inﬂuence of the magnetic ﬁeld, without dose
return to the skin, to show lack of clinically signiﬁcant electron return effect or magnetic ﬁeldeinduced dose distortions. Abbreviations:
CTV Z clinical target volume; GTV Z gross tumor volume; PTV Z planning target volume.
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additional PTV motion margin was required. Prescribed
dose to the PTV was 36 Gy in 20 fractions of 1.80 Gy
each. Step-and-shoot intensity modulated radiation ther-
apy planning was completed using the dedicated TPS of
the MRgRT system.
Brieﬂy, the hybrid MRgRT system used for this patient
consists of a split-solenoid 0.35-T superconducting mag-
net, with 3 co-rotating cobalt-60 sources equally distrib-
uted, mounted on a gantry sandwiched by the magnet.
Multileaf collimators positioned under each source pro-
vide beam shaping and full shielding. The system can
deliver from all 3 sources simultaneously while imaging
in the sagittal plane at a rate of 4 frames per second. The
presence of the magnetic ﬁeld is taken into account during
treatment planning by the Monte Carloebased TPS inte-
grated in the MRgRT device. For this pediatric patient,
the presence of the magnetic ﬁeld during treatment pre-
sented 2 concerns. The ﬁrst was the effect of the magnetic
ﬁeld on the dose distribution both inside and outside the
patient. The second was the need for anesthesia moni-
toring equipment, for which the vault housing the
MRgRT system was not initially designed.
Regarding the ﬁrst of these concerns, previous publi-
cations have reported that the 0.35-T magnetic ﬁeld has
little effect on dose deposition in soft tissue, where the
mean free path of secondary electrons is too short to be
curved by the Lorentz force.9 However, as the beam exits
the patient, secondary electrons created at the exit surface
into air are indeed curved toward a path along the body,
potentially impinging on other parts of the body such as,
in this case, the chin.10 In vivo dosimetry measurements
were performed during the ﬁrst 2 fractions of therapy to
evaluate the peripheral doses in 3 areas: the chin, the
pelvis, and breast (site of particular exposure concern near
the treatment area). Optically stimulated luminescence
dosimeters (Microstar-II, Landauer, Inc, Glenwood, IL)
were placed on the patient’s body and read out immedi-
ately after delivery. Based on these measurements, the
chin and pelvis were estimated to receive about 1% and
0.5% of the total prescription dose, respectively, compa-
rable to peripheral surface doses from standard linear
accelerators (Fig. 1). Comparison with TPS prediction
was made for the optically stimulated luminescence do-
simeters placed near the breast; however, the chin and
pelvis were outside the planning image data set and
therefore outside the calculation grid. The 2 maximum
points measured for the breast were within 3% of the TPS
prediction. Detailed results are presented in Table 1.
Special considerations were also required in this case
for MR-compatible treatment monitoring. The hospital’s
anesthesia team was present for every fraction, and
although their monitoring equipment was MR compatible,
it was not possible to see it inside the room with the
existing patient camera system. A standalone camera with
a tripod was acquired and connected to a laptop computer
placed in the radiofrequency insulated equipment closet
inside the treatment vault. An ethernet cable from this
laptop was fed via a ﬁlter panel in the equipment closet to
another laptop outside the treatment area, thus eliminating
the concern of reduced MR image quality from moni-
toring equipmenteproduced radiofrequency noise. Pre-
liminary testing was performed with this equipment set up
and a homogenous, liquid spherical phantom to evaluate
the signal-to-noise ratio compared with baseline; no
change in signal-to-noise ratio was detected.
All treatment fractions were delivered with a custom
immobilization device and real-time MR guidance,
including cine MR gating on the target volume, based on
the exhale phase during free breathing, using the
described monitoring for daily sedation. At time of clin-
ical setup for each treatment fraction, the patient
underwent high-resolution volumetric MRI at exhale-
breath-hold in the treatment position and was then
aligned to the GTV to maximize plan/tumor overlap.
Gating window targets and settings were selected by the
treating physician and evaluated on each treatment day.
Table 1 In vivo peripheral dose measurements with optically stimulated luminescence dosimeters for chin, pelvis, and breast areas
Measurement point Measured dose per
fraction (cGy)




Difference between TPS and
measurement (%)
Chin 1 2.04 40.8 - -
Chin 2 2.03 40.6 - -
Chin 3 2.05 41 - -
Pelvis 1 0.81 16.2 - -
Pelvis 2 0.85 17 - -





109.13 2182.6 2242.5 2.70%
Abbreviation: TPS Z treatment planning system.
Comparisons with the treatment planning system predictions are shown where available.
Advances in Radiation Oncology: AprileJune 2019 Pediatric MRgRT 235
Downloaded for Anonymous User (n/a) at Washington University School of Medicine from ClinicalKey.com by Elsevier on April 24, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
Details of MR guidance with cine MR gating, as imple-
mented at our institution for standard clinical practice,
have been previously published.8
The decision to proceed with MRgRT resulted in
improved sparing of normal tissues. As described earlier,
a 0.5-cm CTV to PTV expansion was used in this case to
better account for intrafraction motion via real-time cine
MRI beam gating on the target. Had the patient been
treated without MR guidance for motion management
(using standard cone beam CTebased image guidance
instead), the comparison-planned PTV expansion would
have been 1.0 cm because of the need to account for both
respiratory motion of the diaphragmatic target and setup
uncertainty. This would have resulted in a 59% larger
PTV volume (357.8 cm3 vs the 224.8 cm3 PTV volume
treated here). Thus, 133 cm3 more normal tissue,
including the adjacent diaphragm, lungs, liver, and heart,
would have been treated in the absence of MRgRT
technology, given that any additional PTV expansion
would comprise a hollow sphere of additional normal
tissue around the target (357.8 cm3 e 224.8 cm3
Z 133 cm3).
Regarding treatment outcome, the patient tolerated all
treatment fractions without identiﬁed acute toxicity.
Speciﬁcally, she had no nausea, vomiting, or diarrhea
during or immediately after radiation treatment; her par-
ents noted only mild fatigue. At 28 months after radiation,
the patient remained without evidence of local or distant
disease recurrence and without identiﬁed late toxicity
attributable to radiation treatment.
Conclusions
This is the ﬁrst described clinical use of MRgRT for a
pediatric patient. In this reported case, MRgRT was used
to maximize soft-tissue visualization and daily setup ac-
curacy while optimizing the management of motion in a
highly mobile (diaphragmatic) disease site to minimize
treatment volumes. Delivery of MRgRT to a pediatric
patient requires several unique technical considerations,
including the use of MR-compatible anesthetic
monitoring, but has been successfully and safely accom-
plished in a routine clinical setting. As MRgRT enters
widespread clinical use, indications in the pediatric pop-
ulation for applications such as online adaptive radiation
therapy and motion management to better spare normal
tissues while maintaining target coverage are likely to
expand.
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